He added that Relation will generate novel datasets from physiologically relevant human disease systems capable of surfacing biological mechanisms that support future discovery work, combining "advanced experimental capabilities and computational approaches to create a valuable resource for understanding disease." “Our collaboration with GSK focuses on generating large-scale human cellular perturbation datasets and advancing next-generation cellular foundation models like MORGAN. Roblin chose GSK because both companies believe that combining high-quality human biology data with advanced AI is key to future drug discovery. "Relation contributes automated experimentation, industrial-scale generation of multi-omic perturbation data and the development of cellular foundation models like MORGAN. GSK brings deep disease expertise and decades of experience advancing therapies from discovery into the clinic."